Filing Details

Accession Number:
0001104659-25-049671
Form Type:
13G Filing
Publication Date:
2025-05-14 20:00:00
Filed By:
ADAR1 Capital Management
Company:
Grace Therapeutics Inc. (NASDAQ:GRCE)
Filing Date:
2025-05-15
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
ADAR1 Capital Management, LLC 0 1,501,473 9.99%
ADAR1 Capital Management GP, LLC 0 1,502,143 9.99%
Daniel Schneeberger 0 1,501,473 9.99%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  (1) Includes (i) 183,779 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 6,033 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 1,311,661 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR Partners, LP and Spearhead Insurance Solutions IDF, LLC as of May 14, 2025. Excludes 2,932,081 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. (2) Based on 13,718,106 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of March 7, 2025 reported in the Issuer's S-3, filed with the SEC on March 10, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) Includes (i) 183,779 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP and (ii) 1,318,364 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR Partners, LP as of May 14, 2025. Excludes 2,416,088 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. (2) Based on 13,718,106 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of March 7, 2025 reported in the Issuer's S-3, filed with the SEC on March 10, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) Includes (i) 183,779 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 6,033 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 1,311,661 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR Partners, LP and Spearhead Insurance Solutions IDF, LLC as of May 14, 2025. Excludes 2,932,081 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. (2) Based on 13,718,106 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of March 7, 2025 reported in the Issuer's S-3, filed with the SEC on March 10, 2025.


SCHEDULE 13G


 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:05/15/2025
 
ADAR1 Capital Management GP, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:05/15/2025
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:05/15/2025